{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T01:30:24Z","timestamp":1787880624305,"version":"build-2784847793"},"reference-count":0,"publisher":"American Diabetes Association","issue":"5","content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[1980,9,1]]},"abstract":"<jats:p>The feasibility of reducing the fasting blood glucose (FBG) level to &amp;lt;6 mmol\/L has been studied in all 84 maturity-onset diabetic (MOD) patients in three general practices. Only 35 (48%) were initially \u201cwell controlled\u201d by this criterion, although 72 (86%) had no postprandial glycosuria. Seventy-one patients were monitored for 6 mo. With additional oral hypoglycemic therapy where necessary, the number of \u201cwell controlled\u201d increased from 29 (41%) to 54 (76%), associated with a significant decrease in the hemoglobin A1. The patients were subsequently assessed at two 3-monthly intervals, and a fasting plasma glucose &amp;gt;4 and &amp;lt;6 mmol\/L was usually maintained. All but two patients with a fasting glucose level &amp;lt; 6 mmol\/L had fasting triglyceride concentrations &amp;lt; 2 mmol\/L. The fasting blood glucose can be assayed in general practice with glucose-oxidase strips, and control by this means is simpler, cheaper, and more effective than regular urine glucose monitoring.<\/jats:p>","DOI":"10.2337\/diacare.3.5.607","type":"journal-article","created":{"date-parts":[[2007,3,5]],"date-time":"2007-03-05T22:51:27Z","timestamp":1173135087000},"page":"607-610","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":35,"title":["Control of Maturity-Onset Diabetes by Monitoring Fasting Blood Glucose and Body Weight"],"prefix":"10.2337","volume":"3","author":[{"given":"S","family":"Howe-Davies","sequence":"first","affiliation":[{"name":"Diabetes Research Laboratories, Nuffield Department of Clinical Medicine, Radcliffe Infirmary\u2008Oxford"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R W","family":"Simpson","sequence":"additional","affiliation":[{"name":"Diabetes Research Laboratories, Nuffield Department of Clinical Medicine, Radcliffe Infirmary\u2008Oxford"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R C","family":"Turner","sequence":"additional","affiliation":[{"name":"Diabetes Research Laboratories, Nuffield Department of Clinical Medicine, Radcliffe Infirmary\u2008Oxford"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/3\/5\/607\/464587\/3-5-607.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/3\/5\/607\/464587\/3-5-607.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T14:11:57Z","timestamp":1647094317000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/3\/5\/607\/21246\/Control-of-Maturity-Onset-Diabetes-by-Monitoring"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1980,9,1]]},"references-count":0,"journal-issue":{"issue":"5","published-print":{"date-parts":[[1980,9,1]]}},"URL":"https:\/\/doi.org\/10.2337\/diacare.3.5.607","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[1980,9,1]]}}}